Skip to content


Repatha (evolocumab) is an antibody pharmaceutical. Evolocumab was first approved as Repatha on 2015-07-17. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.
Trade Name Repatha
Common Name Evolocumab
Indication atherosclerosis, dyslipidemias, hypercholesterolemia
Drug Class Monoclonal antibodies: fully human, cardiovascular indications
Get full access now